Choose Your Country or Region

PF-4708671

Name: PF-4708671
Brand: Selleck Chemicals
SKU: S2163
Rating: 5 (41 reviews)

Licensed and Manufactured by Pfizer Catalog No.S2163

For research use only.

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

CAS No. 1255517-76-0

Selleck's PF-4708671 has been cited by 41 publications

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Related Compound Libraries

Other S6 Kinase Products

LY2584702^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
Laduviglusib (CHIR-99021)^New

Laduviglusib (CHIR-99021, CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B. BI-D1870 exhibits anticancer attributes including the generation of reactive oxygen species (ROS) and increases in endoplasmic reticulum (ER) stress and autophagy.
Rapamycin (AY-22989)

Rapamycin (AY-22989, Rapamune, Sirolimus, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.
Laduviglusib (CHIR-99021) HCl

Laduviglusib (CHIR-99021; CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001, SDZ-RAD) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.

Download Inhibitor Catalog

S6 Kinase Signaling Pathway Map

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

BHT-101	NIewPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwOEKwNlQh\|ryP	M{XYOHNCVkeHUh?=
UACC-893	M1nSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkO5TWM2OD13LkG5PFg3KM7:TR?=	MnHqV2FPT0WU
A427	M4ewZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTVwN{K1Olch\|ryP	M{nTXXNCVkeHUh?=
OCUB-M	M{DYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzSTWM2OD14Lk[2NVAzKM7:TR?=	M4DlTnNCVkeHUh?=
SW684	M1vRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTdwNUKyOlgh\|ryP	MmXYV2FPT0WU
SK-LMS-1	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWS5OYhTUUN3ME25MlAyOzB{IN88US=>	Mn\QV2FPT0WU
CP50-MEL-B	MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPpSFlKSzVyPUmuN\|A1OTlizszN	MYXTRW5ITVJ?
NCI-H1651	M2XaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HVOGlEPTB;MUCuNFI4PiEQvF2=	NUHiR2JoW0GQR1XS
ABC-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTKTWM2OD1zMD6xNFM4KM7:TR?=	MUfTRW5ITVJ?
OE19	M{XI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlu3TWM2OD1zMD6xO\|M{KM7:TR?=	MmX2V2FPT0WU
DSH1	M3TYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEn4cXBKSzVyPUGwMlg5PzlizszN	MXfTRW5ITVJ?
SW13	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jhd2lEPTB;MUGuPVMyQSEQvF2=	NHnuTXdUSU6JRWK=
MDA-MB-453	MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTF{LkG2NFMh\|ryP	NIO1ZpBUSU6JRWK=
647-V	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWK2NJdrUUN3ME2xNk4{PTh{IN88US=>	M2XkUXNCVkeHUh?=
NCI-H2342	NX\3PGV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moq2TWM2OD1zMj6zPVk2KM7:TR?=	NGX2U5VUSU6JRWK=
LB2241-RCC	MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXqTWM2OD1zMj61O\|c6KM7:TR?=	NWL6[otmW0GQR1XS
UACC-257	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTF\|LkS0OVMh\|ryP	MVHTRW5ITVJ?
NCI-H661	Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTF\|Lk[0OFkh\|ryP	MknsV2FPT0WU
FADU	M3HNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYSyd3JiUUN3ME2xN{43QTl{IN88US=>	MVfTRW5ITVJ?
A2780	M3;oVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33QO2lEPTB;MUOuPFA1OSEQvF2=	NWXtVYFJW0GQR1XS
NCI-H1793	NVnad2ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTF2LkSwPFUh\|ryP	MmrxV2FPT0WU
TE-8	M2LUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1naT2lEPTB;MUWuN\|Q3PSEQvF2=	MnzRV2FPT0WU
HGC-27	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mny0TWM2OD1zNj6xOlQ1KM7:TR?=	NYHSXWZHW0GQR1XS
MMAC-SF	M1LSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXzbVdsUUN3ME2xO{4{PzJ5IN88US=>	NVXGWWhMW0GQR1XS
Calu-6	NE\mR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTF6LkG1NVMh\|ryP	Mn62V2FPT0WU
HUTU-80	NGnIZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmmxTWM2OD1zOD6zPVU6KM7:TR?=	NYTienRVW0GQR1XS
SAS	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;ITWM2OD1zOD62OFU2KM7:TR?=	MnTjV2FPT0WU
IST-MES1	Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLORoxsUUN3ME2xPE43PTB6IN88US=>	NYLNU2x[W0GQR1XS
C3A	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF6xe2lKSzVyPUG4Mlc6OTlizszN	Mn6xV2FPT0WU
ES3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTF6LkizOlQh\|ryP	MXHTRW5ITVJ?
HSC-2	M3\kS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3n2RWlEPTB;MUmuOlU1OSEQvF2=	NGjDe2tUSU6JRWK=
T47D	MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\ITWM2OD1{MD6xOFg2KM7:TR?=	M1;xO3NCVkeHUh?=
EW-7	NEHaTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIixWWlKSzVyPUKwMlg2QDhizszN	NIS3bXZUSU6JRWK=
LN-405	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDOTWM2OD1{MD64PVY2KM7:TR?=	M4nBT3NCVkeHUh?=
U031	NFvuZ\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWq1RWY5UUN3ME2yNU41QDB{IN88US=>	MnrDV2FPT0WU
A549	NXrxT3FsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTJzLki0PVEh\|ryP	MYDTRW5ITVJ?
RMG-I	M{HYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzMTWM2OD1{Mj6yOlY5KM7:TR?=	NWnV[WZJW0GQR1XS
BT-474	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfNTWM2OD1{Mj62OVUyKM7:TR?=	NWr1VmlHW0GQR1XS
NB69	M37zSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvjdWxKSzVyPUKzMlE2OiEQvF2=	NXXmV5cxW0GQR1XS
NB7	M{WzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\WdmlEPTB;MkSuNVg5KM7:TR?=	MYjTRW5ITVJ?
HCC1569	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTJ2Lk[xNlUh\|ryP	MX\TRW5ITVJ?
MEL-JUSO	M2j4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTJ2Lk[5NFgh\|ryP	NULP[lFIW0GQR1XS
MDA-MB-175-VII	NG[wPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfHc2lZUUN3ME2yOU4zPTF5IN88US=>	NULHUmtbW0GQR1XS
HCC1419	NUiyZ\|NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknjTWM2OD1{NT62NFA{KM7:TR?=	MmDTV2FPT0WU
Ca9-22	NF[4RWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljjTWM2OD1{NT62OFMzKM7:TR?=	M2ryUXNCVkeHUh?=
KGN	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIezc2dKSzVyPUK1Mlc2PDdizszN	M3TuOnNCVkeHUh?=
LB373-MEL-D	NGS2WIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojHTWM2OD1{Nj6xPVM5KM7:TR?=	MXrTRW5ITVJ?
NCI-H1755	NHLFSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPtNJpPUUN3ME2yOk45QDRzIN88US=>	NXHHXlJ6W0GQR1XS
D-423MG	MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHH[HFKSzVyPUK3MlA4OTVizszN	NHXaU\|NUSU6JRWK=
DK-MG	NUDOS\|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\0TWM2OD1{OD63PFQ3KM7:TR?=	M1njfHNCVkeHUh?=
NCI-H1623	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTJ6LkizOFIh\|ryP	MlTDV2FPT0WU
KU-19-19	Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{OwSWlEPTB;MkiuPVk2KM7:TR?=	NUfwWFE1W0GQR1XS
C-33-A	M175Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{noNGlEPTB;MkmuNlE6QCEQvF2=	MWDTRW5ITVJ?
SCC-4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TGNGlEPTB;M{CuN\|M2PCEQvF2=	M2P3dXNCVkeHUh?=
MG-63	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnxSnVKSzVyPUOwMlU6QTRizszN	NF7UeJpUSU6JRWK=
LNCaP-Clone-FGC	NWnRZ3lrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fQTmlEPTB;M{GuOFkzOSEQvF2=	NEGxdZdUSU6JRWK=
CAPAN-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXPTWM2OD1\|MT61Nlg3KM7:TR?=	NG\wVoRUSU6JRWK=
GI-ME-N	NG\OcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTNzLkWzOVMh\|ryP	M4ThXnNCVkeHUh?=
RERF-LC-MS	M4ewSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPITWM2OD1\|Mj62O\|Q4KM7:TR?=	M16wXnNCVkeHUh?=
KLE	NXXjW4FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrObpJ{UUN3ME2zN{41OzN2IN88US=>	M2rE[XNCVkeHUh?=
KNS-81-FD	NYjEOZNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjYTVJKSzVyPUOzMlUxODhizszN	MXnTRW5ITVJ?
DOK	NWq2UnBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1e1WWlEPTB;M{SuOlYyOiEQvF2=	NVP2bndHW0GQR1XS
ACHN	NVPub3VMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfMTWM2OD1\|NT6xOVg5KM7:TR?=	NX\4UFNMW0GQR1XS
KYSE-520	NVPLb4l6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULtbZZEUUN3ME2zOU4zOzZzIN88US=>	MWDTRW5ITVJ?
SBC-5	NX;1bVBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlyyTWM2OD1\|NT61NVE3KM7:TR?=	M1PGeXNCVkeHUh?=
NCI-H28	MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPpSJNUUUN3ME2zOU43Pjl3IN88US=>	M1rBcXNCVkeHUh?=
ES7	Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTN4LkKyOFkh\|ryP	M3z0bHNCVkeHUh?=
A172	Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlr3TWM2OD1\|Nj60NVg4KM7:TR?=	NHnQVYJUSU6JRWK=
UM-UC-3	NWPhbY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3jSm9KSzVyPUO3Mlg4PDZizszN	NFTBUJBUSU6JRWK=
LXF-289	MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjhfFRKSzVyPUO4MlAxPDdizszN	M4G3OnNCVkeHUh?=
KP-4	NXf0TGhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmL3TWM2OD1\|OD60O\|M6KM7:TR?=	NXPDRpFzW0GQR1XS
TE-1	NIjBfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTN7Lk[1PFkh\|ryP	NXvaZYtGW0GQR1XS
G-402	NH62OWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTRyLkC2NUDPxE1?	MVjTRW5ITVJ?
786-0	Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTRyLkmwPVYh\|ryP	MoTOV2FPT0WU
K5	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PuPWlEPTB;NEGuN\|Y5PiEQvF2=	NUfITYxRW0GQR1XS
SK-N-DZ	M1fHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DmRWlEPTB;NEGuN\|gzOyEQvF2=	NVnWO4l7W0GQR1XS
OVCAR-4	NV34WGRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1r4N2lEPTB;NEGuO\|U3QCEQvF2=	NI\qWpBUSU6JRWK=
T84	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;CdnhKSzVyPUSyMlEzPjNizszN	NFjNPWZUSU6JRWK=
GCIY	NIPqZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjybYRKSzVyPUSzMlA5ODNizszN	NXSwZWhwW0GQR1XS
BB49-HNC	NYW4XIROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml:0TWM2OD12Mz6zN\|Q5KM7:TR?=	MUnTRW5ITVJ?
SNU-C2B	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jyRmlEPTB;NEOuOlQ{PiEQvF2=	M{HmXXNCVkeHUh?=
TE-6	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTYTWM2OD12Mz64PFk1KM7:TR?=	NH:xb45USU6JRWK=
23132-87	NX\IZoh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjHTWM2OD12ND6yPVc5KM7:TR?=	M4DObXNCVkeHUh?=
DMS-53	NXXZWZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTWd5NLUUN3ME20OE4{Ozh2IN88US=>	MmTiV2FPT0WU
ONS-76	NF\BbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\nTWM2OD12ND63OlYyKM7:TR?=	MYjTRW5ITVJ?
DMS-273	NXK0fG9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvsRWFbUUN3ME20OE46PDNizszN	M2PCeHNCVkeHUh?=
COLO-824	M3HR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTR3Lki3O\|Uh\|ryP	NWCxVVlyW0GQR1XS
DMS-114	M1zZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjhZ2hGUUN3ME20OU45QTJ5IN88US=>	MnrNV2FPT0WU
YKG-1	NHrvVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjNZ2x{UUN3ME20Ok4xOzV3IN88US=>	NEjkR4hUSU6JRWK=
RH-18	MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTR4LkO3N\|Mh\|ryP	NWO5R4FHW0GQR1XS
NCI-H1355	NGHYbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33x[2lEPTB;NE[uOlE5KM7:TR?=	MoG1V2FPT0WU
NCI-H2170	M2jIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWX0U5dlUUN3ME20O{44PTh2IN88US=>	NFq3N3pUSU6JRWK=
OC-314	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTVN2xKSzVyPUS3Mlg1PzhizszN	MVTTRW5ITVJ?
NCI-H2030	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\xSWlEPTB;NEeuPFkxPiEQvF2=	NYrkTWxkW0GQR1XS
22RV1	MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHKWVFKSzVyPUS3MlkxOTVizszN	NEe5fJpUSU6JRWK=
G-401	NWPuO4hiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTR6LkS0NVUh\|ryP	MXPTRW5ITVJ?
YAPC	NETGc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HiZmlEPTB;NEmuPFA4OyEQvF2=	M2nuUnNCVkeHUh?=
SW1573	NGHw[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDuTWM2OD13MD6yOFM2KM7:TR?=	MWnTRW5ITVJ?
COLO-792	NXHWTI9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XDdGlEPTB;NUCuOlI{PyEQvF2=	NH3xS2RUSU6JRWK=
KNS-62	MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXoTWM2OD13MD63OVA5KM7:TR?=	MlfzV2FPT0WU
NB5	M{fwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUm4dVJCUUN3ME21NU41PTB7IN88US=>	NGfOUmRUSU6JRWK=
CP66-MEL	M2DCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTVzLk[0NFgh\|ryP	MlnIV2FPT0WU
CaR-1	M2fGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HRbmlEPTB;NUKuNFYxPiEQvF2=	NVvTN\|BDW0GQR1XS
CAL-54	Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTV{LkGxNFIh\|ryP	MnPyV2FPT0WU
8305C	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHOZYFKSzVyPUWyMlMyPSEQvF2=	MWDTRW5ITVJ?
Calu-3	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHTXXVKSzVyPUWyMlM4OzNizszN	NFLOWoRUSU6JRWK=
AU565	NEnQPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHaTWM2OD13Mj61OVA6KM7:TR?=	MnvYV2FPT0WU
CW-2	NGLEW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O3PGlEPTB;NUKuPFY2PCEQvF2=	MWnTRW5ITVJ?
BEN	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rDfGlEPTB;NUOuO\|g3OiEQvF2=	NH;OOnlUSU6JRWK=
NCI-H1975	MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYmx[WpsUUN3ME21N{45QTZ4IN88US=>	MYDTRW5ITVJ?
HCT-116	NXTCZXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmT1TWM2OD13ND6wN\|I4KM7:TR?=	MoG1V2FPT0WU
SH-4	NVfW[I1ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknyTWM2OD13ND6xN\|gh\|ryP	MV7TRW5ITVJ?
NCI-H1693	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTV2LkKxNFMh\|ryP	M3fkVnNCVkeHUh?=
BPH-1	NUDSeFd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\XUJBKSzVyPUW1MlI5QTJizszN	NGTiS2hUSU6JRWK=
CAMA-1	MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;6b\|JKSzVyPUW1MlgyOTZizszN	NUDQOmkzW0GQR1XS
A388	NXKzU5luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTV4LkC5PFUh\|ryP	NH7EOXFUSU6JRWK=
C2BBe1	M{nPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4i0SWlEPTB;NU[uNlY{PCEQvF2=	MYHTRW5ITVJ?
GAMG	NEDPfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\uPG5KSzVyPUW2MlU6PTVizszN	MmL4V2FPT0WU
MKN28	NHqyfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17QdGlEPTB;NU[uPFAyOyEQvF2=	NWiwTFZkW0GQR1XS
VA-ES-BJ	MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fOPGlEPTB;NU[uPFc1PSEQvF2=	NH;KW4pUSU6JRWK=
HuCCT1	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXHfJFKSzVyPUW3MlA1QTJizszN	M2nkS3NCVkeHUh?=
BFTC-905	NX7Cc41bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnLWW13UUN3ME21O{4zQDl6IN88US=>	MlLxV2FPT0WU
LS-123	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjoXXpqUUN3ME21O{42PjZ6IN88US=>	MXvTRW5ITVJ?
LB996-RCC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3RUoFKSzVyPUW4MlAzQDdizszN	M2jTcHNCVkeHUh?=
NCI-H1048	NH\BdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1yyOWlEPTB;NUiuNlE5QCEQvF2=	NF;uSWpUSU6JRWK=
COR-L105	MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XuTGlEPTB;NUiuO\|M{PyEQvF2=	NV2yWpVvW0GQR1XS
OVCAR-8	Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TX[GlEPTB;NUmuNVcyPiEQvF2=	NY[yXXR4W0GQR1XS
SK-N-FI	NY\PdXBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HocGlEPTB;NUmuN\|IxPyEQvF2=	NEDBcHNUSU6JRWK=
MES-SA	NYnSWJJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXmSW5pUUN3ME21PU41PTB7IN88US=>	M{LDR3NCVkeHUh?=
SCC-9	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTxUpE6UUN3ME21PU41PzV\|IN88US=>	MkmzV2FPT0WU
EFO-27	NXj4fmx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVX5TJhEUUN3ME21PU46PDNizszN	NV[wZmMxW0GQR1XS
GT3TKB	NUC3bndWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TXdWlEPTB;NkCuOlA1QCEQvF2=	MX7TRW5ITVJ?
HCC38	M4nFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHMTWM2OD14MT60N\|c6KM7:TR?=	MmrQV2FPT0WU
MLMA	M2HLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4r2XWlEPTB;NkGuOlE3OyEQvF2=	NXzyVFlxW0GQR1XS
D-566MG	NE\xWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPkdZRKSzVyPU[zMlUzOjRizszN	MWfTRW5ITVJ?
SF295	MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr1TWM2OD14Mz62OlU2KM7:TR?=	NXHmSXAzW0GQR1XS
ES4	M4Xkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7wXnlQUUN3ME22OE41PzF7IN88US=>	NF\C[YxUSU6JRWK=
CAKI-1	NV;GfWVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{G5e2lEPTB;NkSuOVczOSEQvF2=	NVnIdVNlW0GQR1XS
OAW-28	NGnFTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnneIFKSzVyPU[0Mlk3PDdizszN	NYLXXYROW0GQR1XS
NCI-H460	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTZ3LkC4PVch\|ryP	M4LTeHNCVkeHUh?=
JAR	NGXiW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TjOmlEPTB;NkWuOVUyPiEQvF2=	NITET41USU6JRWK=
SNU-449	NEfuNJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXlNZhKSzVyPU[1Mlc3OTZizszN	NYPybIhXW0GQR1XS
D-392MG	M4fScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPz[pRQUUN3ME22OU46PDN2IN88US=>	Mly1V2FPT0WU
EW-22	M33hVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvYTWM2OD14Nj6zPVUh\|ryP	MYnTRW5ITVJ?
GCT	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLRTWM2OD14Nz6wOFQ{KM7:TR?=	M33IS3NCVkeHUh?=
NOS-1	NWfpb3g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzMTllKSzVyPU[3MlY5PjdizszN	NW\kTYJPW0GQR1XS
RH-1	M{Hme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\U[2lEPTB;NkiuOVU2QSEQvF2=	MmXjV2FPT0WU
HuH-7	NFXhdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmizTWM2OD14OT6xNFAzKM7:TR?=	NYXPe3UxW0GQR1XS
NUGC-3	M4LlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTdyLkm2OFQh\|ryP	M{C3fXNCVkeHUh?=
IST-SL1	NX76U2RST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4npPGlEPTB;N{GuNlMzPCEQvF2=	NELacFBUSU6JRWK=
SHP-77	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIK1eXVKSzVyPUeyMlEyQSEQvF2=	M3fOVnNCVkeHUh?=
SW1116	M{Dpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH20eXVKSzVyPUeyMlE1ODdizszN	MVrTRW5ITVJ?
LK-2	M3GwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXNSYZ{UUN3ME23Nk45PjF{IN88US=>	NVmzW\|FzW0GQR1XS
U-2-OS	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTd\|LkG4Nlgh\|ryP	NWDqNpA5W0GQR1XS
KYSE-150	M{j3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XiTGlEPTB;N{OuOlEyQCEQvF2=	MXvTRW5ITVJ?
U251	M1PiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:wTWM2OD15Mz64NVY5KM7:TR?=	Mon1V2FPT0WU
HT-1080	NH:1d2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfBS5FKSzVyPUe0MlI2PzRizszN	M1\NOnNCVkeHUh?=
NCI-H1437	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXqOYNKSzVyPUe0MlY{OjZizszN	NG\xcmJUSU6JRWK=
HPAF-II	NXj3dXZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknwTWM2OD15ND62OFE2KM7:TR?=	M4XrR3NCVkeHUh?=
Becker	NE\yeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2T1NWlEPTB;N{WuNVExPSEQvF2=	M3j2e3NCVkeHUh?=
PANC-10-05	NWjVToRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX64eI1YUUN3ME23OU4zQDZ3IN88US=>	NGjSR\|NUSU6JRWK=
TYK-nu	NESwdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVG3XpRLUUN3ME23OU4{OTB{IN88US=>	NYHSd\|czW0GQR1XS
SKG-IIIa	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvRTWM2OD15NT6zN\|QyKM7:TR?=	M2fvcXNCVkeHUh?=
NCI-H1993	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXhbW5kUUN3ME23OU44Ozl5IN88US=>	MmPFV2FPT0WU
S-117	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTPUZVTUUN3ME23OU44PTVizszN	MoTEV2FPT0WU
HuO9	NFT2c5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LW[mlEPTB;N{[uNFA1QCEQvF2=	M2i2VnNCVkeHUh?=
CAL-51	NEC1UXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX:wR2VuUUN3ME23Ok4yODB4IN88US=>	MYnTRW5ITVJ?
BT-20	M4nqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTd4LkKxOlgh\|ryP	NFrXVo5USU6JRWK=
LB831-BLC	Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjFdXNKSzVyPUe2MlMzOTdizszN	MnfiV2FPT0WU
LB1047-RCC	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{O2dWlEPTB;N{[uO\|YyQSEQvF2=	MWjTRW5ITVJ?
ES8	NHn2fIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;BW5E{UUN3ME23PE4xODd\|IN88US=>	MVHTRW5ITVJ?
UMC-11	M2D0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mle5TWM2OD15OD6wPFg1KM7:TR?=	NIHlNo5USU6JRWK=
NCI-H226	M33LcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jHRWlEPTB;N{iuNVMyPSEQvF2=	M1;acnNCVkeHUh?=
IGROV-1	NUjNSXBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTd6LkW1OUDPxE1?	NFPs[mxUSU6JRWK=
BHY	NX\Yd4NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml:wTWM2OD15OT61PVYh\|ryP	M1rHWXNCVkeHUh?=
MKN45	Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRThyLkOxO\|Qh\|ryP	NE\yb4lUSU6JRWK=
IA-LM	NGi0T2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoSyTWM2OD16MD6zOVEyKM7:TR?=	NID1UXBUSU6JRWK=
WM-115	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzCTWM2OD16MT60NVE1KM7:TR?=	NF;pVFlUSU6JRWK=
VMRC-RCZ	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRThzLkS0NlUh\|ryP	MVvTRW5ITVJ?
NCI-H2291	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX36PWZ2UUN3ME24NU43QDR{IN88US=>	NVO1OGU2W0GQR1XS
MCF7	NYnCWllWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYOxe4ZHUUN3ME24N{4zQDl5IN88US=>	MUTTRW5ITVJ?
639-V	NWWyeYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPpTWM2OD16ND62NVI6KM7:TR?=	M1zp[3NCVkeHUh?=
RT4	MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3ZTWM2OD16NT6yOFA{KM7:TR?=	MonEV2FPT0WU
NCI-H2405	M1zIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{[xRmlEPTB;OEWuNlk6PyEQvF2=	NF7JUIpUSU6JRWK=
CAL-33	M{f5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmD2TWM2OD16NT62N\|E2KM7:TR?=	NHvqS\|hUSU6JRWK=
BT-549	M{XzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHZbmtUUUN3ME24OU46Ozh{IN88US=>	MUHTRW5ITVJ?
HT-1197	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLLeoVKSzVyPUi4MlExPzdizszN	NEfneWhUSU6JRWK=
G-361	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HJ[GlEPTB;OEiuNVQ4PCEQvF2=	NF3VToJUSU6JRWK=
LS-411N	M{\4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2WzVGlEPTB;OEmuN\|M5QCEQvF2=	NFPyWXFUSU6JRWK=
HT-144	MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHsN2ZKSzVyPUi5MlU6QTJizszN	NHT4fpJUSU6JRWK=
DJM-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjuPZNOUUN3ME24PU45QDR3IN88US=>	NH23Z3JUSU6JRWK=
CAL-12T	M4C5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T2U2lEPTB;OUCuO\|g6PSEQvF2=	NHLIUolUSU6JRWK=
MKN7	NHfwbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M331VmlEPTB;OUGuN\|U2OSEQvF2=	NGHzSIpUSU6JRWK=
HuP-T3	M3vzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWf4OGM5UUN3ME25Ok4yODB2IN88US=>	M{O2cXNCVkeHUh?=
SK-MG-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTl4LkGzOFgh\|ryP	NV3Ke492W0GQR1XS
NCI-H2347	MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q1T2lEPTB;OUiuNVA1OiEQvF2=	MljnV2FPT0WU
SW872	NHz4VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTFyMD60OVYh\|ryP	NETnfopUSU6JRWK=
COLO-829	MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXofFNKSzVyPUGwNE42PTNizszN	Mlf3V2FPT0WU
MC-IXC	M3TC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHwTWM2OD1zMECuOlE2KM7:TR?=	MXHTRW5ITVJ?

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-mTOR / mTOR / p-p70S6K / p70S6K ; pS6 / S6 / pS6K / S6K1 / pAKT / AKT	30423811 28626016
Growth inhibition assay	Cell viability	30423811

Protocol (from reference)

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing. Click to purchase: PEG400 Tween 80	30 mg/mL

Chemical Information

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

Download PF-4708671 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):